Landogrozumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Landogrozumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetGDF-8
Clinical data
SynonymsLY2495655
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6338H9790N1694O1988S42
Molar mass142.9 kDa g·mol−1

The pharmaceutical drug Landogrozumab (LY2495655) (INN) is a humanized monoclonal antibody designed for the treatment of muscle wasting disorders.[1][2]

This drug was developed by Eli Lilly & Co.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Landogrozumab, American Medical Association.
  2. ^ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113" (PDF). WHO Drug Information. 29 (2).